Episode 271: PREMIUM – DESCARTES, OSLER, ODYSSEY and what you need to know
In episode 271, James and Mike discuss the most recent evidence for two new monoclonal antibody medications that lower lipids. We discuss the two new studies OSLER and ODYSSEY. At the end we both agree that it is great these studies looked at cardiovascular events and at least they are going in the right direction. However, we still have a long way to go before we would consider using them.
Show notes
Study synopses can be found at mystudies.org
DESCARTES
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
OSLER
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
ODYSSEY LONG TERM
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Listening to this episode is for premium podcast members only. If you already have a membership, login to your account. If you aren't yet a premium subscriber, sign up today!
